The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...